Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Hypochondroplasia and Acanthosis nigricans: a new syndrome due to the p.Lys650Thr mutation in the fibroblast growth factor receptor 3 gene?

Authors: Castro-Feijoo, L  Loidi, L  Vidal, A  Parajes, S  Roson, E  Alvarez, A  Cabanas, P  Barreiro, J  Alonso, A  Dominguez, F  Pombo, M 
Citation: Castro-Feijoo L, etal., Eur J Endocrinol. 2008 Sep;159(3):243-9. doi: 10.1530/EJE-08-0393. Epub 2008 Jun 26.
Pubmed: (View Article at PubMed) PMID:18583390
DOI: Full-text: DOI:10.1530/EJE-08-0393

BACKGROUND: Hypochondroplasia (HCH) is a skeletal dysplasia inherited in an autosomal dominant manner due, in most cases, to mutations in the fibroblast growth factor receptor 3 (FGFR3). Acanthosis nigricans (AN) is a velvety and papillomatous pigmented hyperkeratosis of the skin, which has been recognized in some genetic disorders more severe than HCH involving the FGFR3 gene. OBJECTIVE AND DESIGN: After initial study of the proband, who had been consulted for short stature and who also presented AN, the study was extended to the patient's mother and to 12 additional family members. METHODS: Clinical, biochemical and radiological studies were performed on the family. In addition, exons 11 and 13 of FGFR3 were analyzed. RESULTS: The proband and ten relatives presented HCH plus AN and the analysis of FGFR3 showed the p.Lys650Thr mutation. The members with normal phenotypes were non-carriers of the mutation. CONCLUSION: This is the first report of a large pedigree with the clinical phenotype of HCH plus AN due to a FGFR3 mutation, p.Lys650Thr. This finding demonstrates the coexistence of both conditions due to the same mutation and it might represent a true complex, which should be further established by searching for AN in mild HCH patients or for HCH in patients with AN.


Disease Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 11568026
Created: 2016-12-06
Species: All species
Last Modified: 2016-12-06
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.